Current Report Filing (8-k)
May 02 2019 - 4:35PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 2, 2019
CytoDyn Inc.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-49908
|
|
83-1887078
|
(State or other jurisdiction
of incorporation)
|
|
(SEC
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
1111 Main Street, Suite 660
Vancouver, Washington
|
|
98660
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
(360) 980-8524
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☐
If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
|
|
|
|
|
On May 2, 2019, the Company posted an updated version of the investor presentation deck titled Leronlimab (PRO 140) HIV -
Cancer to its website at www.cytodyn.com. A copy of the investor presentation is filed as Exhibit 99.1 to this
Form 8-K.
The Company does not intend to incorporate any contents from its website into this
Form 8-K.
Item 9.01.
|
Financial Statements and Exhibits.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
CytoDyn Inc.
|
|
|
|
|
May 2, 2019
|
|
|
|
By:
|
|
/s/ Michael D. Mulholland
|
|
|
|
|
Name:
|
|
Michael D. Mulholland
|
|
|
|
|
Title:
|
|
Chief Financial Officer
|
CytoDyn (QB) (USOTC:CYDY)
Historical Stock Chart
From Mar 2024 to Apr 2024
CytoDyn (QB) (USOTC:CYDY)
Historical Stock Chart
From Apr 2023 to Apr 2024